Patent Yard Sign in
Expired European patentEurope

Defective recombinant adenoviruses for gene therapy of tumours

EP 0695360 B1 · Applicant: Aventis Pharma S.A.

EPO PDF

Overview

The published document from the EPO: abstract, claims, description and drawings. Open it full size

Read the whole patent

Listed from its EPO record in Patent Yard's archive of European patents past their term. Its claims, description and drawings are in the EPO PDF and on Google Patents, and the Claude kit works from them.

Google PatentsEPO PDF

Why it's free to use

  • Filed April 15, 1994 and granted July 5, 2006. A European patent lasts at most 20 years from filing, so its term ended April 15, 2014.
  • A supplementary protection certificate, which can extend a medicine or crop-protection patent, adds at most five and a half years, so even that would have ended by October 15, 2019.
  • We check European rights only. A US or other national patent in its family could still be in force: check its family on Espacenet or Google Patents.
FiledApril 15, 1994
PublishedFebruary 7, 1996
GrantedJuly 5, 2006
Term endedApril 15, 2014
Application numberEP 94913649
Classification (CPC)A61K35/761 +2 more

Timeline

Timeline From EPO dates

1995199719992001200320052007200920112013Application filedApril 15, 1994PublishedFeb 7, 1996Patent grantedJuly 5, 2006Term endedApril 15, 2014

Sources & verification

Official EPO records

Full published documentClaims, description and drawings as a PDF.EPOEuropean Patent RegisterProcedure, status, file inspection and legal events.EPOLinked open EP data recordThe bibliographic record this page is built from.EPO

Cross-check elsewhere

Google PatentsFull text, worldwide family, citing patents and legal events.patents.google.comEspacenetNational family members and their legal status.European Patent Office

Everything on this page comes from the EPO record linked above. EPO data used under CC BY 4.0.